Add Yahoo as a preferred source to see more of our stories on Google. pieris Forest Flame with red growth in garden border Pieris are easy-to-grow and cold-hardy evergreen shrubs with dark fingered ...

Pieris' PIRS shares were up almost 8% after it announced that it will receive an undisclosed milestone payment from partner Boston Pharmaceuticals related to its pipeline candidate, BOS-342 (formerly ...

Pieris Pharmaceuticals Inc PIRS shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled respiratory ...

Steve Yoder has been the CEO of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities & ...

Pieris Pharmaceuticals’ PIRS shares were up almost 12% on Jul 18, after management announced strategic update in light of the recent events that have impacted its respiratory franchise. In order to ...

BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® ...

US biotech Pieris Pharmaceuticals has begun a collaboration and supply agreement with Eli Lilly, trialling its cancer drug PRS-343 in combination with the big pharma’s Cyramza (ramucirumab). PRS-343 ...

Pieris is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. The latest price target for Baidu was by Mizuho on Jan.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody-based ...

Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology ...